A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: What do we know, and what are we yet to learn?

Expert Review of Vaccines

Volumn 12, Issue 8, 2013, Pages 837-858

  Martin, Natalie G ^a   Snape, Matthew D ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

immunogenicity; meningococcal; reactogenicity; safety; serogroup B; vaccine

Indexed keywords

ADHESIN; BACTERIAL ANTIGEN; BINDING PROTEIN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; FACTOR H BINDING PROTEIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; NEISSERIA HEPARIN BINDING ANTIGEN; NEISSERIAL ADHESIN A; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANAPHYLACTOID PURPURA; ANTIBODY TITER; APNEA; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; BACTERIAL STRAIN; BETA HEMOLYTIC STREPTOCOCCUS; CHRONIC FATIGUE SYNDROME; CRYING; DEMYELINATION; DRUG SAFETY; EATING HABIT; EUROPE; FEBRILE CONVULSION; FEVER; GROUP B STREPTOCOCCAL INFECTION; GUILLAIN BARRE SYNDROME; HEADACHE; HEARING IMPAIRMENT; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MALAISE; MEMBRANE VESICLE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REACTIVE ARTHRITIS; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SEIZURE; SERUM BACTERICIDAL ACTIVITY; SIDE EFFECT; SOMNOLENCE; SYNOVITIS; VACCINATION; VISUAL IMPAIRMENT;

DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; FEVER; HUMANS; IMMUNIZATION SCHEDULE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B;

EID: 84887807231     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.814862     Document Type: Article

References (110)

1. Nadel S. Prospects for eradication of meningococcal disease. Arch. Dis. Child 97(11), 993-998 (2012
2. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect. Dis. 10(2), 112-124 (2010
3. Holst J, Nokleby H, Bettinger JA. Considerations for controlling invasive meningococcal disease in high income countries. Vaccine 30(Suppl. 2), B57-62 (2012
4. Bottomley MJ, Serruto D, Safadi MA, Klugman KP. Future challenges in the elimination of bacterial meningitis. Vaccine 30 (Suppl. 2), B78-86 (2012
5. Saez-Llorens X, McCracken GH Jr. Bacterial meningitis in children. Lancet 361(9375), 2139-2148 (2003
6. Pace D, Pollard AJ. Meningococcal disease: Clinical presentation and sequelae. Vaccine 30 (Suppl. 2), B3-B9 (2012
7. Ladhani SN, Flood JS, Ramsay ME et al. Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines. Vaccine 30(24), 3710-3716 (2012
8. Halperin SA, Bettinger JA, Greenwood B et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 30(Suppl. 2), B26-B36 (2012
9. Gossger N, Snape MD, Yu L-M et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial. JAMA. 307(6), 573-582 (2012
10. Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51(10), 1127-1137 (2010
11. Snape MD, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: A randomized comparative trial. Pediatr. Infect. Dis. J. 29(11), e71-e79 (2010
12. Santolaya ME, O'Ryan ML, Valenzuela MT et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: A Phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379(9816), 617-624 (2012
13. Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev. Vaccines 10(5), 575-588 (2011
14. Madico G, Welsch JA, Lewis LA et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177(1), 501-510 (2006
15. Veggi D, Gentile MA, Cantini F et al. The factor H binding protein of Neisseria meningitidis interacts with xenosiderophores in vitro. Biochemistry 51(46), 9384-9393 (2012
16. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin. Vaccine Immunol. 18(6), 1002-1014 (2011
17. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27(21), 2794-2803 (2009
18. Beernink PT, Leipus A, Granoff DM. Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin. Vaccine Immunol. 13(7), 758-763 (2006
19. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: Implications for the development of a multicomponent group B vaccine. J. Infect. Dis. 195(10), 1472-1479 (2007
20. Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197(6), 789-799 (2003
21. Fletcher LD, Bernfield L, Barniak V et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72(4), 2088-2100 (2004
22. Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 28(9), 2122-2129 (2010
23. Lucidarme J, Comanducci M, Findlow J et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin. Vaccine Immunol. 17(6), 919-929 (2010
24. Anderson AS, Hao L, Jiang Q et al. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease. Hum. Vaccin Immunother. 9(3), 471-479 (2012
25. Vogel U, Taha MK, Vazquez JA et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: A qualitative and quantitative assessment. Lancet Infect. Dis. 13(5), 416-425 (2013
26. Brunelli B, Del Tordello E, Palumbo E et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 29(5), 1072-1081 (2011
27. Capecchi B, Adu-Bobie J, Di Marcello F et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol. Microbiol. 55(3), 687-698 (2005
28. Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195(11), 1445-1454 (2002
29. Lucidarme J, Comanducci M, Findlow J et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J. Clin. Microbiol. 47(11), 3577-3585 (2009
30. Fagnocchi L, Pigozzi E, Scarlato V, Delany I. In the NadR regulon, adhesins and diverse meningococcal functions are regulated in response to signals in human saliva. J. Bacteriol. 194(2), 460-474 (2012
31. Serruto D, Spadafina T, Ciucchi L et al. Neisseria meningitidis GNA2132, a heparinbinding protein that induces protective immunity in humans. Proc. Natl Acad. Sci. USA. 107(8), 3770-3775 (2010
32. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis. 188(11), 1730-1740 (2003
33. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA. 103(29), 10834-10839 (2006
34. Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338(8775), 1093-1096 (1991
35. Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin. Infect. Dis. 49(4), 597-605 (2009
36. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: A safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23(17-18), 2191-2196 (2005
37. Holst J, Martin D, Arnold R et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl. 2), B3-B12 (2009
38. Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13(9), 821-829 (1995
39. de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lance, 340(8827), 1074-1078 (1992
40. Rouaud P, Perrocheau A, Taha MK et al. Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. Euro surveillance 11(7), 178-181 (2006
41. Sotologo Padron F, Huergo CC, Gil V, Diaz E, Valdespino I, Gotera N. Cuban meningococcal BC vaccine: Experience and contributions from 20 years of application. MEDICC Rev. 9(1), 16-22 (2007
42. van der Ley P, van den Dobbelsteen G. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum. Vaccines 7(8), 886-890 (2011
43. Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol. 16(2), 156-162 (2009
44. Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29(7), 1413-1420 (2011
45. Wong S, Lennon D, Jackson C et al. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr. Infect. Dis. J. 26(4), 345-350 (2007
46. Wong SH, Lennon DR, Jackson CM et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr. Infect. Dis. J. 28(5), 385-390 (2009
47. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin. Vaccine Immunol. CVI 18(3), 483-486 (2011
48. Vesikari T, Esposito S, Prymula R et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials. Lancet 381(9869), 825-835 (2013
49. Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum. Vaccines 7(6), 646-653 (2011
50. Snape M, Philip J, John T et al. Bactericidal antibody persistence two years following immunization with two investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of pre-school booster doses; a follow-on study to a randomized clinical trial. Paediatr. Infect. Dis. J. (2013) (In Press
51. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol. 13(4), 486-491 (2006
52. McNicholas A, Galloway Y, Stehr-Green P et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Hum. Vaccines 3(5), 196-204 (2007
53. Jackson C, Lennon DR, Sotutu VTK et al. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Arch. Dis. Child. 94(10), 745-751 (2009
54. Jackson C, Lennon D, Wong S et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch. Dis. Child. 96(8), 744-751 (2011
55. Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 25(16), 3075-3079 (2007
56. Tatley MV, Kunac DL, McNicholas A et al. The Intensive Vaccines Monitoring Programme (IVMP): An electronic system to monitor vaccine safety in New Zealand. Vaccine 26(22), 2746-2752 (2008
57. Sexton K, McNicholas A, Galloway Y et al. Henoch-Schonlein purpura and meningococcal B vaccination. Arch. Dis. Child. 94(3), 224-226 (2009
58. Stehr-Green P, Galloway Y, Kieft C, McNicholas A. The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand. N. Z. Med. J. 120(1263), U2746 (2007
59. Stehr-Green P, Radke S, Kieft C, Galloway Y, McNicholas A, Reid S. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand. Vaccine 26(6), 739-742 (2008
60. Nokleby H. Neurological adverse events of immunization: Experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine. Expert Rev. Vaccines 6(5), 863-869 (2007
61. Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25(16), 3080-3084 (2007
62. Magnus P, Brubakk O, Nyland H et al. Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome. Vaccine 27(1), 23-27 (2009
63. Taha MK, Zarantonelli ML, Alonso JM et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 25(14), 2537-2538 (2007
64. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann. 14(2), 195-207; discussion 208-110 (1991
65. Martin N, Snape M, Robinson H et al. Reactogenicity of investigational serogroup B meningococcal vaccines given at 40 months of age to primed and vaccine naive children. Presented at: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany, 9-14 September 2012.
66. Prymula R, Siegrist CA, Chlibek R et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: Two open-label, randomised controlled trials. Lancet 374(9698), 1339-1350 (2009
67. Prymula R, Esposito S, Kittel C, Kohl I, Toneatto D, Dull P. Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunizations. Poster. Presented at: 29th European Society for Paediatric Infectious Diseases Meeting. The Hague, The Netherlands (2011
68. Hua W, Izurieta HS, Slade B et al. Kawasaki disease after vaccination: Reports to the vaccine adverse event reporting system 1990-2007. Pediatr. Infect. Dis. J. 28(11), 943-947 (2009
69. Kuo HC, Yang KD, Chang WC, Ger LP, Hsieh KS. Kawasaki disease: An update on diagnosis and treatment. Pediatr. Neonatol. 53(1), 4-11 (2012
70. Rowley AH. Kawasaki disease: Novel insights into etiology and genetic susceptibility. Ann. Rev. Med. 62, 69-77 (2011
71. Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J. Epidemiol. 22(2), 79-85 (2012
72. Heuclin T, Dubos F, Hue V et al. Increased detection rate of Kawasaki disease using new diagnostic algorithm, including early use of echocardiography. Pediatr. 155(5), 695-699 e691 (2009
73. Boccadifuoco G, Brunelli B, Pizza MG, Giuliani MM. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine. J. Prevent. Med. Hyg. 53(2), 56-60 (2012
74. Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl. Acad. Sci. USA 107(45), 19490-19495 (2010
75. Vogel U, Taha M-K, Findlow J et al. Strain coverage of a multicomponent meningococcal vaccine (4cMenB) in Western Europe. In: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany (2012
76. Bettinger JA, Scheifele DW, Halperin SA et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine (2013) (Epub ahead of print
77. Tzanakaki G, Kesanopoulos K, Xirogianni A et al. Retrospective analysis of Meningococcal Antigen Typing System (MATS) on serogroup B meningococcal isolates in Greece. Presented at: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany (2012
78. Abad R, Luca O, Fabio R et al. Strain coverage of a meningococcal mulitcomponent (4CMenB) vaccine in Spain. Presented at: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany (2012
79. Nissen M, Tozer S, Whiley D et al. Use of the Meningococcal Antigen Typing System (MATS) to Assess the Australian Meningococcal Strain Coverage with a Multicomponent Serogroup B Vaccine. Presented at: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany, 9-14 September 2012.
80. Lemos AP, Gorla MC, Brandileone MC et al. MATS based coverage prediction for the 4CMenB Vaccine on Neisseria meningitidis B (MenB) Brazilian invasive strains. Presented at: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany, 9-14 September 2012.
81. Claus H, Kriz P, Musilek M et al. Strain coverage of a multi-component meningococcus B vaccine in the Czech Republic and in Germany. In: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany (2012
82. Kim E, Paulos S, Carlone G et al. Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States. Presented at: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany (2012
83. Biolchi A, Lo Sapio M, Frosi G et al. Meningococcal Antigen Typing System (MATS) was a conservative estimate of killing when confirmed in a serum bactericidal assay using human complement (hSBA). Presented at: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany (2012
84. Holst J, Santini L, Rigat F et al. Comparison of flow-cytometry (FACS) and meningococcal antigen typing system (MATS) as predictors of serum bactericidal activity using human complement (hSBA) on pathogenic isolates collected during an endemic period in Norway (2005-2006). In: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany (2012
85. Claus H, Borrow R, Taha M-K et al. Potential coverage of the 4CMenB vaccine in non-B meningococci. Presented at: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany (2012
86. Hong E, Giuliani MM, Deghmane AE et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine 31(7), 1113-1116 (2012
87. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359(9320), 1829-1831 (2002
88. Simmini I, Boccadifuoco G, Zhao X et al. Characterisation of the 4CMenB vaccine components on strains isolated during a carrier survey in Italy, by MATS and Molecular Epidemiology analysis. Presented at: 18th International Pathogenic Neisseria Conference. Wurzburg, Germany (2012
89. Read R, Baxter D, Chadwick D, Faust S. Impact of a quadrivalent conjugate (MENACWY-CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students. Presented at: The 31st Meeting of the European Society for Paediatric Infectious Diseases. Milan, Italy, 28 May-1 June (2013
90. Snape MD, Medini D, Halperin SA, DeTora L, Drori J, Moxon ER. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 30(Suppl. 2), B67-B72 (2012
91. Marshall HS, Richmond PC, Nissen MD et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers AGED 18 to 36 months: A Phase 1 randomized controlled clinical trial. Pediatr. Infect. Dis. J. 31(10), 1061-1068 (2012
92. Richmond PC, Marshall HS, Nissen MD et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, Phase 2 trial. Lancet Infect. Dis. 12(8), 597-607 (2012
93. Richmond PC, Nissen MD, Marshall HS et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation Phase 1 trial. Vaccine 30(43), 6163-6174 (2012
94. Keiser PB, Gibbs BT, Coster TS et al. A Phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 28(43), 6970-6976 (2010
95. Pinto VB, Moran EE, Cruz F et al. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 29(44), 7752-7758 (2011
96. Moran EE, Burden R, Labrie JE III et al. Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine. Clin. Vaccine Immunol. 19(5), 659-665 (2012
97. Bonvehi P, Boutriau D, Casellas J, Weynants V, Feron C, Poolman J. Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clin. Vaccine Immun. 17(9), 1460-1466 (2010
98. Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14(10), 1001-1008 (1996
99. Weynants V, Denoel P, Devos N et al. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect. Immun. 77(5), 2084-2093 (2009
100. Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact. Vaccine 31(23), 2638-2646 (2013
101. Andrews N, Stowe J, Wise L, Miller E. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/ acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine 28(44), 7215-7220 (2010
102. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334(6), 349-355 (1996
103. Kitchin N, Southern J, Morris R et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine 27(37), 5096-5102 (2009
104. Kitchin N, Southern J, Morris R et al. A reactogenicity of an acellular pertussiscontaining pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine 24(18), 3964-3970 (2006
105. Jacobsen SJ, Ackerson BK, Sy LS et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 27(34), 4656-4661 (2009
106. Klein NP, Fireman B, Yih WK et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 126(1), e1-e8 (2010
107. Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps, rubella, and varicella vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 59(RR-3), 1-12 (2010
108. Klein NP, Lewis E, Baxter R et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics 129(5), 809-814 (2012
109. O'Leary ST, Suh CA, Marin M. Febrile seizures and measles-mumps-rubella- varicella (MMRV) vaccine: What do primary care physicians think? Vaccine 30(48), 6731- 6723 (2012
110. Policy statement-Prevention of varicella: Update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics 128(3), 630-632 (2011